Celgene and Forma have agreed to a broad collaboration in the field of protein homeostasis, which involves quality-control pathways in cells that play roles in cancer, neurodegenerative disorders and other diseases.
CardioDx, a 2012 Fierce 15 winner, has partnered with India's Core Diagnostics to distribute its coronary artery disease test in the country's burgeoning market.
GE Healthcare's PET imaging agent designed to help spot Alzheimer's disease drew in another international drug company partner developing a treatment in the space.
AstraZeneca's partnership spree of the last two months has gone Down Under. As the company shrinks its internal research work force, AstraZeneca has tapped Brisbane, Australia-based Alchemia to hunt for small molecule drugs against multiple disease targets.
Like most of its new drug programs in recent years, Merck's work on new hepatitis C drugs has never quite paid off as hoped. Now it's taken its lead clinical-stage program for MK-5172 and tied up with Bristol-Myers Squibb to test a combo approach with daclatasvir.
While AstraZeneca's busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the other Cambridge.
The drug giant, which is in the process of renovating its R&D wing, has hired on the crafty Cambridge, MA-based biotech Bind Therapeutics to work on a kinase inhibitor nanotech drug for treating cancer.
The agreement follows the start of a Phase I study of the compound, EPZ-5676, for which biotech giant Celgene has partnered with the startup for development outside the U.S.
Founded just 5 years ago, Combat Medical Systems nailed down an $86 million U.S. Department of Defense contract to provide a slew of medical equipment and devices for military and federal agencies over the next 5 years.
Santaris Pharma has found another major pharma partner for its RNA drug platform. Bristol-Myers Squibb has forked over $10 million initially and promised much more to collaborate with Santaris on discovery and development of new genetic therapies.